Search results
Showing 31 to 45 of 85 results for colitis
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease
NICE is unable to make a recommendation on vedolizumab (Entyvio) for treating chronic refractory pouchitis after surgery for ulcerative colitis in adults. This is because Takeda did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA826
Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis
Transabdominal artificial bowel sphincter implantation for faecal incontinence (IPG276)
Evidence-based recommendations on transabdominal artifical bowel sphincter implantation for faecal incontinence. This involves inserting an artificial sphincter through a cut in the abdomen.
View recommendations for IPG276Show all sections
Sections for IPG276
High dose rate brachytherapy for carcinoma of the cervix (IPG160)
Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.
View recommendations for IPG160Show all sections
Sections for IPG160
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy.
Spondyloarthritis in over 16s: diagnosis and management (NG65)
This guideline covers diagnosing and managing spondyloarthritis that is suspected or confirmed in adults who are 16 years or older. It aims to raise awareness of the features of spondyloarthritis and provide clear advice on what action to take when people with signs and symptoms first present in healthcare settings. It also provides advice on the range of treatments available.
Find out more about the NICE technology appraisal advisory committee B members and their registered interests
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]
Awaiting development [GID-TA10717] Expected publication date: TBC
Clostridium difficile infection: risk with broad-spectrum antibiotics (ESMPB1)
Summary of the evidence on the risk of using broad-specturm antibiotics associated with clostridium difficile infection
check for signs of bowel cancer in people aged 18 and over with ulcerative colitis or Crohn's disease (types of inflammatory bowel...
Guselkumab for treating moderately to severely active ulcerative colitis TS ID 10713
Awaiting development [GID-TA11247] Expected publication date: TBC
Evidence-based recommendations on leukapheresis for inflammatory bowel disease. This involves removing a small number of white blood cells from the person’s blood.
View recommendations for IPG126Show all sections
Sections for IPG126
This is a summary of the most common accessibility changes we are making in guidelines, and why
Show all sections